SANUWAVE Health, Inc. Common Stock (SNWV) — Analysis Summary
SANUWAVE Health, Inc. Common Stock (SNWV) has a market cap of $50.99M with year-over-year revenue growth of +36.3%. Net margin stands at 26.8%. The stock trades at a P/E ratio of 3.2.
Key Takeaways
- Revenue changed +36.3% year-over-year
- Net margin of 26.8%
- P/E ratio of 3.2
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, SNWV posted revenue growth of +36.3% and trades at a P/E of 3.2.
SANUWAVE Health, Inc. Common Stock (SNWV)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
D/E at 11.2x — extreme leverage
Debt/EBITDA at 5.3x — elevated leverage
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
55
Headquarters
EDEN PRAIRIE, MN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.